Medical approach to pituitary tumors
- PMID: 25248595
- DOI: 10.1016/B978-0-444-59602-4.00020-4
Medical approach to pituitary tumors
Abstract
Transsphenoidal surgery and medical treatment are the cornerstones of the management of pituitary adenomas. However, the optimal therapy should be chosen based on the type of tumor, the patient, and the tumor characteristics. For nonfunctional adenomas surgery is still the first-line treatment. However, for prolactinomas surgery has been replaced by medical treatment. In the other functional pituitary adenomas a more balanced approach is needed to decide between surgery and medical therapy as first-line treatment. In the majority of cases a combination of treatment modalities is needed. In acromegaly and TSH-secreting adenomas medical treatment has a more prominent role than in Cushing's disease. In this chapter the efficacy and side-effects of the different medical therapies is discussed according to adenoma type.
Keywords: Cushing's disease; Pituitary tumor; acromegaly; dopamine agonist; nonfunctional adenoma; pasireotide; pegvisomant; pituitary adenomas; prolactinoma; somatostatin analogs; thyrotropic adenoma.
© 2014 Elsevier B.V. All rights reserved.
Similar articles
-
[Treatment of pituitary adenomas].Orv Hetil. 2009 Sep 27;150(39):1803-10. doi: 10.1556/OH.2009.28584. Orv Hetil. 2009. PMID: 19758960 Review. Hungarian.
-
Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.Ann Endocrinol (Paris). 2015 Feb;76(1):43-58. doi: 10.1016/j.ando.2014.10.002. Epub 2014 Nov 11. Ann Endocrinol (Paris). 2015. PMID: 25556152 Review.
-
Diagnosis and treatment of pituitary adenomas.Minerva Endocrinol. 2004 Dec;29(4):241-75. Minerva Endocrinol. 2004. PMID: 15765032 Review.
-
Future treatment strategies of aggressive pituitary tumors.Pituitary. 2009;12(3):261-4. doi: 10.1007/s11102-008-0154-y. Pituitary. 2009. PMID: 19003539 Free PMC article. Review.
-
The Role of Dopamine Agonists in Pituitary Adenomas.Endocrinol Metab Clin North Am. 2020 Sep;49(3):453-474. doi: 10.1016/j.ecl.2020.05.006. Epub 2020 Jul 15. Endocrinol Metab Clin North Am. 2020. PMID: 32741482 Review.
Cited by
-
Recent Therapeutic Advances in Pituitary Carcinoma.J Immunother Precis Oncol. 2022 Dec 13;6(2):74-83. doi: 10.36401/JIPO-22-25. eCollection 2023 May. J Immunother Precis Oncol. 2022. PMID: 37214211 Free PMC article. Review.
-
Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells.J Neurooncol. 2015 Oct;125(1):79-89. doi: 10.1007/s11060-015-1895-x. Epub 2015 Aug 22. J Neurooncol. 2015. PMID: 26297046
-
Medical combination therapies in Cushing's disease.Pituitary. 2015 Apr;18(2):253-62. doi: 10.1007/s11102-015-0641-x. Pituitary. 2015. PMID: 25647330
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical